[Conference Materials, Panel to Review GP-160 Vaccine Candidate (1992: Bethesda, Maryland)]

REMARKS*
BY
BERNADINE HEALY, M.D.**
GOOD AFTERNOON, AND THANK YOU FOR SETTING
ASIDE YOUR OTHER RESPONSIBILITIES ON RATHER
SHORT NOTICE TO ATTEND THIS MEETING. I HAVE
CONVENED THIS MEETING UNDER THE AUTHORITIES OF
THE NATIONAL INSTITUTES OF HEALTH'S ADVISORY
COMMITTEE TO THE DIRECTOR. WE HAVE COME
TOGETHER TODAY TO DISCUSS THE MANDATE THAT THE
NIH RECENTLY RECEIVED FROM THE CONGRESS TO
DETERMINE THE SCIENTIFIC MERITS OF GP-160, A
DRUG THAT MAY PROVE TO BE EFFECTIVE IN TREATING
INDIVIDUALS WHO ARE INFECTED WITH THE HIV VIRUS.
*PRESENTED TO THE NIH PANEL TO REVIEW GP-160
VACCINE CANDIDATE, NOVEMBER 5, 1992.
**DIRECTOR, NATIONAL INSTITUTES OF HEALTH,
BETHESDA, MARYLAND.